Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Theobromine
Theobromine (3,7-dimethylxanthine) is a naturally-occurring stimulant of the methylxanthine class. It is the principal alkaloid in chocolate, substantially weaker than its close relative caffeine.[1] Theobromine is an adenosine receptor antagonist, producing its effects by blocking the brain's sleep-promoting adenosine signals.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Isolated from cacao beans in 1841 by Russian chemist Alexander Woskresensky, it was soon used as a diuretic and mild heart stimulant.[2] More potent drugs displaced it from medicine over the 20th century. Today it is consumed universally in chocolate and cocoa products and sold freely as a dietary supplement.
Subjective effects include mild vasodilation, slight warmth, increased urination, and a subtle decrease in the sense of calm. The experience is defined by its near-absence — at the highest dose studied in isolation, no measurable change in alertness or mental performance was detected.[3] Adverse effects at high intake include nausea, tachycardia, and restlessness.
Theobromine produces no documented physical dependence and no human fatality has been attributed to it alone. Adverse effects increase above 850 mg/day;[4] the primary risk at high sustained doses is metabolic and cardiovascular rather than acute poisoning. Decades of dietary exposure data and multiple intervention studies inform its safety profile, though no large standalone clinical trials have been completed.
History[edit]
Discovery
Theobromine was first isolated from cacao beans in 1841 by Russian chemist Alexander Woskresensky.[2] The first chemical synthesis followed in 1882, achieved by Hermann Emil Fischer, whose broader work on purine chemistry earned the 1902 Nobel Prize.[2]
Therapeutic History
Through the late 19th and early 20th centuries, theobromine was used clinically as a diuretic, vasodilator, and mild cardiac stimulant.[5] More potent and selective drugs gradually displaced it from all three roles.
Modern Research
Interest revived through cocoa epidemiology. A 15-year cohort study found an inverse association between cocoa intake and cardiovascular mortality,[6] and theobromine was identified as the most bioavailable compound in human plasma after cocoa consumption.[7] A 2005 trial found it suppressed cough more effectively than codeine[8] — opening further research into neuroprotection[9] and cognitive enhancement.[10]
The name theobromine derives from Theobroma, meaning "food of the gods" in Greek. Despite appearances, it contains no reference to the element bromine — a persistent misconception. The -ine suffix simply marks it as an alkaloid.
Chemistry[edit]
Structural Class
Theobromine belongs to the xanthine family of purine alkaloids, sharing a bicyclic scaffold with caffeine and theophylline. The three compounds differ only in methylation pattern: theobromine carries methyl groups at N-3 and N-7; caffeine carries three (N-1, N-3, N-7).[5] The missing N-1 methyl group reduces theobromine's potency at adenosine receptors and limits its ability to cross into the brain.[1]
Molecular Properties
Its molecular formula is C₇H₈N₄O₂ (molecular weight 180.16 g/mol).
Stereochemistry
Theobromine is achiral — no stereoisomers exist.
Physical Properties
It presents as a white crystalline powder with a melting point of approximately 357 °C and is very slightly soluble in water at room temperature.citation needed
Pharmacology[edit]
Mechanism of Action
Theobromine works mainly through two mechanisms: blocking adenosine receptors and inhibiting phosphodiesterases — enzymes that break down intracellular signaling molecules. At both targets it is substantially weaker than caffeine or theophylline.[1] Phosphodiesterase inhibition raises signaling molecules in smooth muscle and kidney tissue, contributing to bronchodilation, vasodilation, and increased urination.[5]
Theobromine barely engages the adenosine receptor subtype responsible for caffeine's wakefulness and alertness.[9] This is why high doses produce no measurable alertness in humans.[3] It also directly calms sensory nerve activation in airway tissue — the basis of its cough-suppressing effect[8] — and inhibits platelet clumping in blood.[12]
Pharmacokinetics
Oral bioavailability approaches 100% from aqueous solution and approximately 80% from a chocolate matrix.[13][14] Theobromine is the most bioavailable compound in human plasma after cocoa consumption — exceeding caffeine, epicatechin, and procyanidins.[7] The half-life is approximately 10 hours; smoking increases clearance by about 33%,[15] and one week of high daily use did not alter pharmacokinetic parameters.[13]
Neuroscience[edit]
Where It Acts
Theobromine's central effects operate through adenosine receptor blockade, but its weak ability to enter the brain limits the impact at dietary doses.[1] In laboratory preparations, it enhanced basal synaptic signaling in the hippocampus while impairing long-term memory strengthening, depending on which receptor type was engaged.[9]
The adenosine receptor subtype most linked to wakefulness and dopamine-mediated alertness is barely engaged by theobromine at concentrations achievable through oral dosing.[1] This explains why 700 mg produced no measurable alertness or psychomotor enhancement in humans.[3]
Neuroprotection and Growth Factors
In a laboratory model of Alzheimer's disease, theobromine prevented memory-related synaptic loss caused by toxic amyloid-β peptides.[9] Dark chocolate consumption also correlated with elevated nerve growth factor — a protein supporting the memory-related neurons implicated in Alzheimer's — over a 30-day trial.[10] Whether these effects translate to clinical benefit at dietary doses remains unstudied.
- Does theobromine cross the blood-brain barrier at sufficient concentrations to produce meaningful effects from dietary doses? Its lower lipophilicity relative to caffeine suggests limited penetration, but direct measurement has not been reported.
- Can the neuroprotective effects observed in Alzheimer's disease models[9] translate to human benefit at achievable plasma concentrations?
- Does chronic theobromine exposure alter adenosine receptor density? No receptor imaging studies have examined this question, which is central to understanding tolerance potential.
Subjective Effects[edit]
Theobromine is a substance where the experience is defined by what is absent rather than what is present. Even at concentrations far above those delivered by food, the expected stimulant qualities — mental sharpening, mood elevation, arousal — do not materialize.[3] The body notices it; the mind does not.
Where caffeine produces clear wakefulness and psychomotor enhancement, theobromine — even at much higher doses — barely registers as stimulation. Chocolate's rewarding qualities arise from the combined sensory and pharmacological action of both compounds together with sweetness and fat[11] — not from theobromine alone.
First isolated from cacao beans in 1841 by Alexander Woskresensky,[2] theobromine was briefly employed as a clinical diuretic and vasodilator before more potent agents displaced it. Today it is consumed universally in chocolate and cocoa products and is commercially available as an unscheduled dietary supplement.
Subjective effects include mild vasodilation, decreased self-reported calmness, and increased urination. The experience is defined by its near-absence — at 700 mg oral, the highest controlled dose studied, no measurable change in alertness or psychomotor performance was detected.[3] No psychological adverse effects, perceptual disturbances, or mood destabilization have been documented at any dose.
Theobromine produces no documented physical dependence and carries wide safety margins in humans, with no recorded fatalities from the compound alone. Adverse effects increase above 850 mg/day;[4] the primary risk at sustained high doses is metabolic and cardiovascular rather than acute poisoning. Multiple intervention studies and decades of dietary exposure data inform the current understanding, though no large clinical trials of theobromine as a standalone pharmaceutical have been completed.
History[edit]
Discovery
Theobromine was first isolated from cacao beans in 1841 by the Russian chemist Alexander Woskresensky, identified as a crystalline alkaloid distinct from caffeine.[2] The first chemical synthesis from xanthine was achieved in 1882 by Hermann Emil Fischer, whose broader work on purine chemistry earned him the 1902 Nobel Prize.[2]
Therapeutic History
Through the late 19th and early 20th centuries, theobromine found clinical use as a diuretic, vasodilator, and mild cardiac stimulant — applications grounded in its methylxanthine pharmacology.[5] It was gradually displaced by more potent and selective agents, including theophylline for bronchodilation and modern loop diuretics for fluid management.
Modern Research
Contemporary interest re-emerged through cocoa cardiovascular epidemiology. The Zutphen Elderly Study demonstrated an inverse association between cocoa intake and cardiovascular mortality over 15 years,[6] prompting investigation of cocoa's individual bioactive constituents. Theobromine was identified as the most bioavailable compound in human plasma after cocoa consumption,[7] and a 2005 randomized trial demonstrated that it inhibits capsaicin-induced cough more effectively than codeine,[8] establishing it as a candidate non-opioid antitussive and catalyzing further research into neuroprotection[9] and cognitive enhancement.[10]
The name theobromine derives from Theobroma, the genus name for cacao meaning "food of the gods" in Greek. Despite appearances, the name contains no reference to the element bromine — a persistent misconception. The -ine suffix simply marks it as an alkaloid.
Chemistry[edit]
Structural Class
Theobromine belongs to the xanthine family of purine alkaloids, sharing a bicyclic scaffold of fused pyrimidine and imidazole rings with caffeine and theophylline. The three compounds differ only in their methylation pattern: theobromine carries methyl groups at N-3 and N-7, theophylline at N-1 and N-3, and caffeine at all three positions (N-1, N-3, N-7).[5]
The absence of the N-1 methyl group distinguishes theobromine from caffeine and correlates with its reduced potency at adenosine receptors and diminished central nervous system penetration.[1]
Molecular Properties
| Molecular formula | C₇H₈N₄O₂ |
| Molecular weight | 180.16 g/mol |
The molecule bears two carbonyl groups (at C-2 and C-6) and two N-methyl groups. The imidazole ring contributes the C-8 hydrogen and the N-7 methyl, while the pyrimidine ring carries the N-3 methyl and an unsubstituted N-1 nitrogen.
Stereochemistry
Theobromine is achiral with no stereogenic centers. No stereoisomers exist.
Physical Properties
Theobromine presents as a white crystalline powder with a melting point of approximately 357 °C (with decomposition). It is very slightly soluble in water at 25 °C (~0.33 g/L), with solubility increasing substantially in hot water and in dilute acids and bases.citation needed The compound is stable under normal storage conditions.
Pharmacology[edit]
Mechanism of Action
Theobromine acts through two primary mechanisms: adenosine receptor antagonism and phosphodiesterase inhibition. At both targets it is substantially weaker than caffeine and theophylline.[1]
At adenosine receptors, theobromine shows meaningful antagonism only at A1 receptors. Activity at A2A receptors is negligible at concentrations achievable through oral dosing.[9] Blocking A1 receptors facilitates synaptic transmission in the hippocampus, while the minimal A2A activity limits theobromine's ability to produce the wakefulness and alertness associated with caffeine.
Theobromine also inhibits phosphodiesterases, enzymes that break down intracellular signaling molecules (cAMP and cGMP). This raises cAMP and cGMP levels in smooth muscle and kidney tissue, contributing to bronchodilation, vasodilation, and increased urine output.[5] Phosphodiesterase inhibitory potency is substantially weaker than theophylline.[5]
Beyond these core mechanisms, theobromine directly inhibits sensory nerve activation by capsaicin in airway tissue, a peripheral action underlying its antitussive properties.[8] The compound also inhibits platelet clumping independently of cocoa flavanols.[12]
Pharmacokinetics
Oral bioavailability approaches 100% from aqueous solution and approximately 80% from a chocolate matrix.[13][14] Theobromine is the most bioavailable compound from consumed cocoa in human plasma, exceeding caffeine, epicatechin, and procyanidins.[7]
The half-life is approximately 10 hours in methylxanthine-naïve humans,[13] though some sources report 6–8 hours depending on population and prior methylxanthine exposure. Smoking increases clearance by approximately 33% through enzyme induction.[15] One week of high daily consumption did not alter pharmacokinetic parameters, indicating no metabolic self-induction.[13]
In dogs, the elimination half-life is approximately 17.5 hours — nearly double the human value — explaining theobromine's marked toxicity in canines.[16]
Neuroscience[edit]
Where It Acts
Theobromine's central effects are mediated through adenosine receptor antagonism, though its weak CNS penetration relative to caffeine limits the magnitude at dietary doses. In mouse hippocampal preparations, 30 µM theobromine produced dual effects: enhanced basal synaptic transmission through A1 receptor blockade and impaired long-term potentiation through A2A receptor blockade.[9]
The compound's negligible A2A activity at achievable concentrations limits engagement of striatal dopamine pathways — the primary mechanism behind caffeine's alertness and reinforcing properties.[1] This explains why 700 mg theobromine produced no measurable alertness or psychomotor enhancement in humans.[3]
Neuroprotection and Growth Factors
Theobromine prevented memory-related synaptic deficits and neuronal loss in hippocampal preparations exposed to amyloid-β peptides, a model of Alzheimer's disease neurotoxicity.[9] Separately, elevated plasma theobromine from dark chocolate consumption correlated with increased nerve growth factor (NGF) levels in a 30-day trial.[10] NGF supports cholinergic neurons critical to memory, and its deficiency is implicated in Alzheimer's progression.
Whether these neuroprotective effects translate to clinical benefit at dietary theobromine exposures in humans remains unstudied.
- Does theobromine cross the blood-brain barrier at sufficient concentrations to produce meaningful CNS effects from dietary doses? Its lower lipophilicity relative to caffeine suggests limited penetration, but direct measurement of cerebrospinal fluid concentrations has not been reported.
- Can the neuroprotective effects observed in Alzheimer's disease models[9] translate to human benefit at achievable plasma concentrations?
- Does chronic theobromine exposure alter adenosine receptor density? No receptor imaging studies have examined this question, which is central to understanding tolerance potential.
Subjective Effects[edit]
Theobromine's experiential character is defined by subtlety. At dietary doses — the 30–100 mg delivered by a chocolate bar — the compound's central effects are indistinguishable from placebo. Even at 700 mg, the highest dose studied in isolation, the only controlled trial found decreased self-reported calmness and peripheral blood pressure lowering with no detectable change in alertness or psychomotor performance.[3] The experience is predominantly peripheral: mild vasodilation, bronchodilation, and diuresis without the mental sharpening or arousal associated with stimulant compounds.
Where caffeine produces clear wakefulness, mood elevation, and psychomotor enhancement at 100–200 mg, theobromine at three to four times that dose barely registers subjectively. Chocolate's rewarding properties arise from the combined sensory and pharmacological action of theobromine, caffeine, sweetness, and fat[11] — not from theobromine alone.
Effect Grid
Moderate supplement doses of 200–400 mg produce peripheral methylxanthine effects including mild vasodilation, increased urination, and possible mild antitussive activity. Theobromine's antitussive mechanism — direct peripheral inhibition of sensory nerve activation — may begin to be functionally relevant at the upper end of this range.
Subjective psychoactive effects remain minimal to absent. No controlled study has demonstrated measurable stimulation, alertness enhancement, or mood changes at doses below 500 mg. The experiential character at this tier is defined by what is not felt rather than what is.
This range is achievable only through deliberate supplementation with pure theobromine — dietary chocolate consumption alone is unlikely to reach 200 mg in a single sitting.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Heart rate perception changes · Restlessness · Nausea · Dehydration sensation · Dizziness · Vomiting · Trembling
Dizziness · Vomiting · Trembling
Timeline
Absorption begins with near-complete oral bioavailability. No subjective awareness of onset at most doses — theobromine's effects emerge too gradually and subtly for a distinct onset moment to be perceived.
Maximal peripheral effects — mild vasodilation, possible slight decrease in calmness at strong doses. Blood pressure lowering observed at 1 hour post-dose in Mitchell 2011. The subjective peak is barely distinguishable from baseline at common doses.
Gradual decline governed by the approximately 10-hour elimination half-life. Effects dissipate slowly without a distinct offset. The long pharmacokinetic tail means theobromine remains pharmacologically active well after subjective effects (if any were perceived) have resolved.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- caffeine
Toxicity
Theobromine carries wide safety margins in humans. It is classified as Generally Recognized As Safe (GRAS) as a naturally occurring food constituent, with no formal acceptable daily intake established[4] and no human fatalities on record from the compound alone. Doses of 150 mg/day from cocoa were well tolerated in intervention studies.[4]
Adverse effects increase above 850 mg/day and are most pronounced at 1000 mg/day.[4]
Heart and Circulation
At extreme intake, theobromine can produce rapid heart rate. This was documented in a patient consuming approximately 180 g of dark chocolate nightly for two weeks.[16]
Blood Sugar
Theobromine at 500 mg/day for four weeks produced unfavorable blood sugar and insulin responses after meals in a randomized controlled trial.[17] The implications for people with diabetes or impaired glucose tolerance are unknown but warrant caution.
Pregnancy
Theobromine is teratogenic in animals at high doses, producing skeletal malformations similar to other methylxanthines.[18] In rats, delayed bone development occurred at doses exceeding 50× typical human consumption, with no significant effects at doses equivalent to normal chocolate consumption.[19] In rabbits, developmental effects occurred at 125–200 mg/kg/day.[20]
No adequate controlled human data exist. Normal dietary chocolate consumption has not been associated with adverse developmental outcomes.safety citation needed Similar caution to caffeine during pregnancy is generally applied, though specific theobromine limits are not codified.safety citation needed
Species-Specific Toxicity
Dogs are markedly more sensitive to theobromine because they eliminate it much more slowly — roughly 17.5 hours versus approximately 10 hours in humans.[21] Toxic signs begin at approximately 20 mg/kg; muscle tremors and heart rhythm disturbances appear at 40–50 mg/kg, and seizures at around 60 mg/kg. Cats and other companion animals are also susceptible.[21]
Psychological Risks
Theobromine has minimal documented psychological risk at any studied dose. No anxiety, panic, psychosis, or psychiatric destabilization attributable to theobromine alone appears in the literature.[3] No hallucinatory or perceptual disturbances have been associated with the compound at any dose.
Tolerance & Dependence
No controlled studies have examined tolerance to theobromine's subjective or cardiovascular effects. One study confirmed that one week of high daily use did not alter half-life or clearance — ruling out metabolic self-induction.[13]
No physical dependence or withdrawal has been identified. Chocolate craving has been attributed to the combined sensory and pharmacological properties of chocolate, not theobromine alone.[11] Cross-tolerance with caffeine is likely given their shared mechanism but has not been confirmed.citation needed
Drug Interactions
Theobromine is metabolized partly by CYP1A2 and CYP2E1 enzymes.[15] No clinical drug interaction studies for theobromine have been published.safety citation needed
CYP1A2 inducers (cigarette smoking, rifampicin) increase theobromine clearance — smoking by approximately 33%.[15]
CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) are expected to decrease clearance, potentially increasing plasma levels and prolonging effects.
Alcohol may affect theobromine metabolism through CYP2E1 modulation.[15]
Combined with caffeine, the pair produces caffeine-like alertness without additional blood pressure effect.[3]
Flavanol co-ingestion: Theobromine enhances flavan-3-ol bioavailability from cocoa, increasing epicatechin absorption by approximately 21%.[22]
Contraindications
4 knownNo formally established contraindications exist in published clinical guidelines. The following conditions warrant caution:
- Impaired glucose tolerance or diabetes: Theobromine at 500 mg/day produced unfavorable blood sugar responses.[17]
- Pregnancy: Animal data show teratogenicity at high doses.[19][20] Controlled human data are absent.
- Heart rhythm disorders: At extreme doses, theobromine contributes to rapid heart rate.[16]
- CYP1A2 inhibitor use: Potent inhibitors such as fluvoxamine or ciprofloxacin may increase theobromine exposure.[15]
Harm Reduction[edit]
Forms & Identification
Theobromine reaches consumers primarily through chocolate, cocoa products, and dietary supplements. In supplement form it appears as white to off-white powder in capsules, typically 100–400 mg per unit. Third-party testing certifications (USP, NSF) provide the most reliable quality assurance.
The primary concern with supplement identification is verifying that a product labeled as theobromine does not contain undisclosed stimulants. Theobromine's wide safety margins make acute toxicity from mislabeling unlikely at typical supplement doses.
Guidelines
- Start with the lowest available supplement dose (typically 100–200 mg) if using theobromine for the first time outside of food sources.
- Do not exceed 850 mg/day — adverse effects increase above this threshold.
- Allow sufficient time between doses to account for the ~10-hour half-life.
- Individuals with diabetes or impaired glucose tolerance should monitor blood sugar when introducing high-dose theobromine supplementation.
- Keep all chocolate and cocoa products away from dogs and cats — theobromine is significantly more toxic to companion animals than to humans.
Set & Setting
Theobromine's minimal psychoactive profile means set and setting have negligible influence on the experience at any documented dose. No special environmental preparation is required. Those experimenting with high-dose supplementation (above 500 mg) should know that effects are predominantly physical — mild vasodilation and increased urination — rather than cognitive or perceptual.
Aftercare & integration. Theobromine's mild pharmacological profile does not typically require post-experience processing. Those who experience discomfort from high-dose supplementation — nausea, restlessness, rapid heart rate — should reduce the dose on subsequent occasions. The long elimination half-life (~10 hours) means a late-afternoon dose may persist into the evening; timing consumption earlier avoids sleep interference.
Recovery & Support
No theobromine-specific dependence syndrome has been identified. The compound does not produce the withdrawal patterns associated with caffeine or other stimulants. Those wishing to reduce chocolate or cocoa intake may find gradual reduction more comfortable than abrupt cessation, though no clinical guidance specific to theobromine exists. For concerns about compulsive chocolate consumption, standard behavioral support approaches apply.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Theobromine emergencies in humans are exceedingly rare. Recognizing a problem:
- Rapid or irregular heartbeat after consuming large quantities of chocolate or supplements
- Severe nausea or vomiting
- Tremors or restlessness
Immediate steps:
- 1. Stop consuming theobromine-containing products.
- 2. If symptoms are mild (nausea, restlessness), monitor and hydrate.
- 3. If heart rate is rapid, irregular, or accompanied by chest pain, call emergency services.
- 4. Tell the dispatcher what was consumed, approximately how much, and when. Good Samaritan laws exist in many jurisdictions to protect people who call for help.
For dogs: Chocolate poisoning is a veterinary emergency. If a dog has consumed chocolate, contact a veterinarian or animal poison control immediately. Toxic signs in dogs include vomiting, diarrhea, rapid breathing, muscle tremors, and seizures. Do not induce vomiting without veterinary guidance.
Legal Status[edit]
Theobromine is unscheduled in all major jurisdictions and has never been subject to controlled substance proceedings.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled | Food ingredient; available as dietary supplement; not DEA-scheduled. |
| United Kingdom | Unscheduled | Food ingredient; sold freely. Not subject to Psychoactive Substances Act 2016 (food exemption). |
| European Union | Unscheduled | Food ingredient. EFSA has reviewed safety as flavouring substance.[4] |
| Canada | Unscheduled | Food ingredient; available without restriction. |
| Australia | Unscheduled | Food ingredient; available over the counter. |
Legal status can change. This table reflects available information as of the article's last update and is not legal advice. Verify current regulations in your jurisdiction before purchasing or using theobromine supplements.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- caffeine
Toxicity
Theobromine carries wide safety margins in humans. It is classified as Generally Recognized As Safe (GRAS) as a naturally occurring food constituent, with no formal acceptable daily intake established.[4] Doses of 150 mg/day from cocoa were well tolerated in intervention studies.[4] No human fatalities from theobromine alone have been documented.
Adverse effects increase above 850 mg/day and are most pronounced at 1000 mg/day.[4] The animal no-observed-adverse-effect level is approximately 50 mg/kg/day.[4]
Heart and Circulation
At extreme intake levels, theobromine contributes to cardiovascular effects. Rapid heart rate was documented in a patient consuming approximately 180 g of dark chocolate nightly for two weeks.[17]
Blood Sugar
Theobromine at 500 mg/day for four weeks produced unfavorable blood sugar and insulin responses after meals in a randomized controlled trial.[18] The clinical significance for individuals with diabetes or impaired glucose tolerance is unknown but warrants caution.
Pregnancy
Theobromine is teratogenic in animals at high doses, producing skeletal malformations similar to other methylxanthines.[19] In rats, delayed bone development occurred at doses exceeding 50× typical human consumption, with no significant effects at doses equivalent to normal chocolate consumption.[20] In rabbits, developmental effects occurred at 125–200 mg/kg/day.[21]
No adequate controlled human data exist. Normal dietary chocolate consumption has not been associated with adverse developmental outcomes.safety citation needed Similar caution to caffeine during pregnancy is generally applied, though specific theobromine limits are not codified.safety citation needed
Species-Specific Toxicity
Dogs are markedly more sensitive to theobromine due to a slower half-life (~17.5 hours versus ~10 hours in humans).[16] Toxic signs begin at approximately 20 mg/kg, with severe symptoms (muscle tremors, heart rhythm disturbances) at 40–50 mg/kg and seizures at ~60 mg/kg. The oral LD₅₀ in dogs is approximately 100–300 mg/kg.[16] Cats and other companion animals are also susceptible.
Psychological Risks
Theobromine has minimal documented psychological risk at any dose studied. No reports of anxiety, panic, psychosis, or psychiatric destabilization attributable to theobromine alone appear in the literature. At 700 mg, the only controlled study reported decreased self-reported calmness without increased anxiety as such.[3] No hallucinatory, dissociative, or perceptual disturbances have been associated with the compound at any dose.
Tolerance & Dependence
No published controlled studies have examined tolerance to theobromine's subjective or cardiovascular effects. One study confirmed absence of pharmacokinetic tolerance: one week of high daily consumption did not alter elimination half-life, clearance, or metabolite profile.[13]
No theobromine-specific physical dependence or withdrawal has been identified. Chocolate craving has been attributed to the combined sensory and pharmacological properties of chocolate rather than theobromine alone.[11] Cross-tolerance with caffeine is likely given their shared mechanism but has not been confirmed for theobromine specifically.citation needed
Drug Interactions
Theobromine is metabolized partly by CYP1A2 and CYP2E1.[15] No clinical drug interaction studies for theobromine have been published.safety citation needed
CYP1A2 inducers (cigarette smoking, rifampicin) increase theobromine clearance — smoking by approximately 33%.[15]
CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) are expected to decrease clearance, potentially increasing plasma levels and prolonging effects.
Alcohol may affect theobromine metabolism through CYP2E1 modulation.[15]
Combined with caffeine, the pair produces caffeine-like alertness without additional blood pressure effect.[3]
Flavanol co-ingestion: Theobromine enhances flavan-3-ol bioavailability from cocoa, increasing epicatechin absorption by approximately 21%.[22]
Contraindications
4 knownNo formally established contraindications exist in published clinical guidelines. The following conditions warrant caution:
- Impaired glucose tolerance or diabetes: Theobromine at 500 mg/day produced unfavorable blood sugar responses.[18]
- Pregnancy: Animal data show teratogenicity at high doses;[20][21] controlled human data are absent.
- Heart rhythm disorders: At extreme doses, theobromine contributes to rapid heart rate.[17]
- CYP1A2 inhibitor use: Potent inhibitors (fluvoxamine, ciprofloxacin) may increase theobromine exposure.[15]
Harm Reduction[edit]
Forms & Identification
Theobromine reaches consumers primarily through chocolate, cocoa products, and dietary supplements. In supplement form it appears as white to off-white powder in capsules, typically dosed at 100–400 mg per unit. Supplement purity varies between manufacturers, and third-party testing certifications (USP, NSF) provide the most reliable quality assurance. Because theobromine's wide safety margins make acute toxicity from mislabeling unlikely at typical supplement doses, the primary identification concern is verifying that a product labeled as theobromine does not contain undisclosed stimulants.
Guidelines
- Start with the lowest available supplement dose (typically 100–200 mg) if using theobromine for the first time outside of food sources.
- Do not exceed 850 mg/day — adverse effects increase above this threshold.
- Allow sufficient time between doses to account for the ~10-hour half-life.
- Individuals with diabetes or impaired glucose tolerance should monitor blood sugar when introducing high-dose theobromine supplementation.
- Keep all chocolate and cocoa products away from dogs and cats — theobromine is significantly more toxic to companion animals than to humans.
Set & Setting
Theobromine's minimal psychoactive profile means set and setting have negligible influence on the experience at any documented dose. No special environmental preparation is required. Individuals experimenting with high-dose supplementation (above 500 mg) should be aware that effects are predominantly physical — mild vasodilation and increased urination — rather than cognitive or perceptual.
Aftercare & integration. Theobromine's mild pharmacological profile does not typically require post-experience processing. Individuals who experience discomfort from high-dose supplementation (nausea, restlessness, tachycardia) should reduce the dose on subsequent occasions. The long elimination half-life (~10 hours) means effects from a late-afternoon dose may persist into the evening — timing consumption earlier in the day avoids sleep interference.
Recovery & Support
No theobromine-specific dependence syndrome has been identified, and the compound does not produce the withdrawal patterns associated with caffeine or other stimulants. Individuals who feel they are consuming excessive amounts of chocolate or cocoa products and wish to reduce intake may find gradual reduction more comfortable than abrupt cessation, though no clinical guidance specific to theobromine exists. For concerns about compulsive chocolate consumption, standard behavioral support approaches apply.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Theobromine emergencies in humans are exceedingly rare. Recognizing a problem:
- Rapid or irregular heartbeat after consuming large quantities of chocolate or supplements
- Severe nausea or vomiting
- Tremors or restlessness
Immediate steps:
- 1. Stop consuming theobromine-containing products.
- 2. If symptoms are mild (nausea, restlessness), monitor and hydrate.
- 3. If heart rate is rapid, irregular, or accompanied by chest pain, call emergency services.
- 4. Tell the dispatcher what was consumed, approximately how much, and when. Good Samaritan laws exist in many jurisdictions to protect people who call for help.
For dogs: Chocolate poisoning is a veterinary emergency. If a dog has consumed chocolate, contact a veterinarian or animal poison control immediately. Toxic signs in dogs include vomiting, diarrhea, rapid breathing, muscle tremors, and seizures. Do not induce vomiting without veterinary guidance.
Legal Status[edit]
Theobromine is unscheduled in all major jurisdictions and has never been subject to controlled substance proceedings. Its presence in chocolate, tea, and cocoa beverages places it entirely outside controlled substance frameworks. The compound is commercially available as a dietary supplement and food ingredient without restriction.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled | Food ingredient; available as dietary supplement; not DEA-scheduled. |
| United Kingdom | Unscheduled | Food ingredient; sold freely. Not subject to Psychoactive Substances Act 2016 (food exemption). |
| European Union | Unscheduled | Food ingredient. EFSA has reviewed safety as flavouring substance.[4] |
| Canada | Unscheduled | Food ingredient; available without restriction. |
| Australia | Unscheduled | Food ingredient; available over the counter. |
No scheduling action is anticipated. Theobromine's weak psychoactive profile, long history of safe dietary consumption, and absence of abuse liability collectively preclude regulatory interest.
Frequently asked questions
What is Theobromine?
Theobromine is a purine alkaloid and adenosine receptor antagonist of the methylxanthine class, the dominant methylxanthine in chocolate. First isolated from cacao beans in 1841, it acts as a substantially weaker CNS stimulant than caffeine or theophylline.
How long does Theobromine last?
Total duration by route of administration — Oral: 6 – 10 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Theobromine?
Psychedex publishes a dosage table for Theobromine on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Theobromine?
The highest-severity documented interactions for Theobromine: Amphetamines (Dangerous), CBD (Dangerous), Ephedrine, Pseudoephedrine (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Theobromine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Theobromine: tolerance builds none; cross-tolerance develops with caffeine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcTarka SM (1982) The toxicology of cocoa and methylxanthines: a review of the literature — Critical Reviews in Toxicology PMID:6765610
- [6] ^Buijsse B, Feskens EJM, Kok FJ, Kromhout D (2006) Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study — Archives of Internal Medicine doi:10.1001/archinte.166.4.411
references
- [1] ^abcdCamandola S, Plick N, Mattson MP (2019) Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease — Neurochemical Research doi:10.1007/s11064-018-2492-0
- [2]
- [3]
- [4]
- [5] ^abcdTarka SM (1982) The toxicology of cocoa and methylxanthines: a review of the literature — Critical Reviews in Toxicology PMID:6765610
- [6] ^Buijsse B, Feskens EJM, Kok FJ, Kromhout D (2006) Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study — Archives of Internal Medicine doi:10.1001/archinte.166.4.411